Although tumor tissue analysis by IHC remains the gold standard for most clinical molecular analysis for targeted therapy selection (with the exception of NGS for EGFR, BRAF or NTRK gene variants), it faces several biological and technological challenges. Here, BRAF is linked to neoplasm.